Aura Biosciences CEO to Present at H.C. Wainwright Global Investment Conference.

Aura Biosciences CEO Elisabet de los Pinos will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025. The company's lead candidate, bel-sar (AU-011), is in late-stage development for early choroidal melanoma. The live webcast of the presentation will be available on Aura Biosciences' website.

Aura Biosciences (NASDAQ: AURA), a clinical-stage biotechnology company focused on developing precision therapies for solid tumors, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The company's CEO, Elisabet de los Pinos, PhD, will deliver a presentation on September 10, 2025, at 11:00 a.m. ET [1].

The presentation, titled "Aura Biosciences: Revolutionizing Precision Therapies for Solid Tumors," will provide investors with an update on the company's pipeline, including its lead candidate, bel-sar (AU-011), which is currently in late-stage development for early choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer [1].

Investors can access the live webcast through Aura Biosciences' investor relations website. The webcast will be available for replay for 90 days following the presentation date [1].

Aura Biosciences is headquartered in Boston, MA, and is committed to developing innovative global oncology therapies that positively transform the lives of patients. For more information, visit [Aura Biosciences' website] and follow the company on X (formerly Twitter) @AuraBiosciences and LinkedIn [1].

References:
[1] https://www.stocktitan.net/news/AURA/aura-biosciences-to-participate-in-the-h-c-wainwright-27th-annual-quot86qlqomk.html